Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Receivables (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Receivables for 5 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 4152.78% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 4152.78% year-over-year, with the annual reading at $12185.0 for FY2025, N/A changed from the prior year.
  • Receivables for Q4 2025 was $1.6 million at Neuphoria Therapeutics, up from $3516.0 in the prior quarter.
  • The five-year high for Receivables was $9.7 million in Q2 2022, with the low at $3516.0 in Q3 2025.
  • Average Receivables over 4 years is $1.4 million, with a median of $32541.0 recorded in 2024.
  • The sharpest move saw Receivables tumbled 99.89% in 2023, then soared 4152.78% in 2025.
  • Over 4 years, Receivables stood at $9.7 million in 2022, then crashed by 99.89% to $10429.1 in 2023, then soared by 260.36% to $37582.0 in 2024, then skyrocketed by 4152.78% to $1.6 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $1.6 million, $3516.0, and $12185.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.